269 results about "Neuroinflammation" patented technology

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

A Bifidobacterium animalis subsp. lactis for reducing Abeta42 deposition and an application, a name of the Bifidobacterium animalis subsp. lactis is Bifidobacterium animalis subsp. lactis IOB-LO7, and classified as Bifidobacterium animalis subsp. lactis, the Bifidobacterium animalis subsp. lactis IOB-LO7 is preserved in the General Microbiology Center of the China General Microbiological Culture Collection Center (CGMCC) on Dec. 23, 2021, with the collection number of CGMCC No. 24185. By reducing the levels of Aβ42 in the cerebral cortex and hippocampus, clearing Aβ amyloid plaques, improving communication between neurons, reducing brain neuroinflammation, and protecting nerve cells, it helps to restore cognitive function and improve Alzheimer's disease. Additionally, it can also improve gut microbiota imbalance caused by Alzheimer's disease.

This invention relates to diselenylene-bridged mesoporous silica nanoparticles loaded with baicalin and their applications. The invention constructs a ROS-responsive, microglia-inspired Ba@Se-MSN&BV2 nanoplatform targeting the secondary phase of spinal cord injury. The BV2 cell membrane-mediated enrichment at the injury site, combined with the diselenylene-triggered, on-demand release of baicalin, enables targeted intervention in a highly oxidative and pro-inflammatory microenvironment. In vitro and in vivo studies show that Ba@Se-MSN&BV2 can alleviate oxidative stress and mitochondrial dysfunction, inhibit apoptosis, promote axonal and neuronal survival, and improve motor circuit function. This invention provides a new therapeutic target and research direction for neuroinflammatory injuries driven by redox homeostasis disruption, with significant clinical application prospects and social value.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The invention relates to the technical field of medicine, in particular to application of an Acp5 inhibitor in cerebral edema after traumatic brain trauma, and the Acp5 inhibitor comprises a medicine with the ACP5 inhibitor as an active component and a prodrug form of the medicine. According to the invention, through an enzyme-substrate key activation mechanism, a drug is coupled by using an ACP5 specific substrate peptide, dual response release is realized in a lesion area, and the targeting property and the safety are remarkably improved. The prodrug is composed of a core inhibitor module, an ACP5 substrate peptide module and a pH response connection module, and can accurately inhibit ACP5 + macrophage infiltration and reduce encephaledema volume and neuroinflammation. The application can effectively treat acute and chronic encephaledema, reduce off-target effect and side effect, and provide a brand new treatment strategy for traumatic brain trauma.

The invention discloses an application of abscisic acid in preparation of a medicine for improving secondary brain injury after cerebral hemorrhage, the abscisic acid can relieve neuroinflammation and improve neurological function recovery by repairing microglial cell lysosome functions, enhancing phagocytic ability and promoting hematoma removal, and a new medicine strategy is provided for cerebral hemorrhage treatment.

The present application relates to the technical field of probiotics, and particularly relates to a Bifidobacterium breve strain and application of the Bifidobacterium breve strain in prevention or treatment of neurodegenerative diseases and neuroinflammation related to neurodegenerative diseases. Bifidobacterium breve ) BKR006, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) (address: No. 1, Xili Beichen, Chaoyang District, Beijing), and the preservation number is CGMCC No. 36096. The strain in the present application is proved in animal experiments that the strain can not only significantly improve the cognitive function and A beta pathology of AD model animals, but also effectively inhibit neuroinflammation in PD models and improve related cognitive impairment, and has a broad spectrum of neuroprotective effect and good development and application prospect.

The invention relates to methods and compositions for preventing or treating a neuropathology in a subject associated with or induced or caused by a P. gingivalis infection, preventing the deposition of or reducing the level of P. gingivalis gingipain in neuronal tissue, delaying the onset of a P. gingivalis-induced or associated neuropathology, for preventing or slowing the rate of abnormal protein deposition in the neuronal tissue, and / or reducing neuroinflammation, the methods comprising administering an RNA polynucleotide encoding a protein comprising or consisting of: - one or more amino acid sequences of an active site of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto; and / or - the amino acid sequence of one or more adhesin binding motifs (ABMs) of an adhesin domain of an Arg- or Lys-gingipain of P. gingivalis, or a sequence that is at least 80% identical thereto, wherein the polynucleotide is capable of being translated in a mammalian cell.

The invention discloses an mGluR5 small-molecule allosteric modulator and application thereof in inhibition of neuroinflammation, and belongs to the technical field of neuropharmacology and anti-inflammatory drug research, two mGluR5 small-molecule allosteric modulators are obtained by virtual screening through an allosteric pocket targeting mGluR5, the structural formulas of the two mGluR5 small-molecule allosteric modulators are shown in the specification, and the structural formula of the mGluR5 small-molecule allosteric modulators is shown in the specification. The mGluR5 micromolecule allosteric modulator can be used for inhibiting microglial cell inflammation, and can effectively relieve LPS-induced microglial cell NO release.

The application discloses a nano guanido drug system and a preparation method and application thereof, and relates to the technical field of medicine, in particular to a GCOF DHM @CAQK platform, can efficiently deliver drugs to a TBI injury site, can accumulate in a TBI brain injury area, can inhibit neuroinflammation, oxidative stress and protect neuron cells after TBI, can precisely intervene in secondary injury of TBI, and provides a new strategy for improving the prognosis of patients.

The invention provides a traditional Chinese medicine preparation for improving or treating cognitive impairment, and relates to the technical field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine preparation is prepared from morinda officinalis, eclipta, semen boitae, fructus alpiniae oxyphyllae, bighead atractylodes rhizome, valerian, turmeric, rhizoma acori graminei, leech, rhizoma anemarrhenae, dendrobium officinale, endothelium corneum gigeriae galli, hematoxylon and honey-fried licorice root. The traditional Chinese medicine preparation shows remarkable neuroprotection and cognition improvement effects on the cell level and the animal level, in the cell level, the preparation can effectively resist Abeta1-42 induced cell damage, and the protection effect is achieved through multiple ways of improving the cell activity, enhancing the oxidation resistance, inhibiting neuroinflammation and the like; in animal experiments, the preparation can comprehensively improve cognitive impairment of APP / PS1 model mice, including relieving behavioral abnormality, improving spatial learning and memory ability, enhancing new object recognition ability, and effectively reducing deposition of A beta in hippocampus on a molecular level. The invention provides a new thought for improving or treating cognitive impairment.

The application discloses application of PTN in preparation of products for treating cognitive impairment caused by severe infection. The inhibitor of PTN provided by the application can inhibit chronic neuroinflammation, thereby preventing and inhibiting formation and development of late cognitive impairment caused by severe infection, and meanwhile, inhibition of expression or function of PTN can effectively block damage of infiltrating macrophages to microglia cells, thereby providing a new direction for treatment of related diseases.

The application provides application of dimethyl itaconate in prevention and treatment of chronic stress-induced anxiety. The application finds that dimethyl itaconate can inhibit excessive activation of microglial cells in a stress state, improve mitochondrial structure and function abnormalities of the microglial cells, and reduce expression of a lysosome marker CD68, so as to inhibit central nervous inflammation, maintain central nervous immune homeostasis, prevent and relieve anxiety-like behavior induced by chronic stress, and effectively prevent and relieve occurrence and development of chronic stress-induced anxiety (generalized anxiety disorder).

The present invention relates to: a water-soluble substituent-based novel compound having high solubility and a method for preparing same. The novel compound having high solubility of the present invention has repeating units represented by chemical formula 1, and has an excellent anti-inflammatory effect and an excellent effect on diseases caused by oxidative stress and neuroinflammatory diseases, and thus is useful as a health food or a pharmaceutical composition. [Chemical formula 1]

The present invention relates to a vanillic acid derivative compound which can be formed by a dehydration condensation reaction between vanillic acid and catecholamine. The vanillic acid derivative compound according to the present invention is characterized in that it can be used as a therapeutic preparation for Alzheimer's disease and neuroinflammation. In addition, the present invention relates to a therapeutic composition for Alzheimer's disease and a therapeutic composition for neuroinflammation, each of which comprises the compound.

This invention discloses the application of a fluorinated chitosan derivative in the preparation of anti-neuroinflammatory drugs, belonging to the field of biomedical technology. The fluorinated chitosan derivative is the sole active ingredient in the drug. Its structure is a fluorinated acyl chitosan derivative obtained by N-acylation modification of the primary amine group at the C2 position of the chitosan backbone, with the C2 substituent being -NH-C(O)-Rf, where Rf is selected from -CF3, -C2F5, or -C3F7. The degree of substitution of the fluorinated chitosan derivative is 40%, and the weight-average molecular weight is 2-5 kDa. This fluorinated chitosan derivative is used as the active ingredient in the preparation of anti-neuroinflammatory drugs.

The invention discloses an application of a gene ECSCR in preparation of a medicine for treating central nervous system diseases. According to the invention, central nervous system neuroinflammation is treated by adjusting ECSCR expression. ECSCR is a gene with obviously increased expression in spinal cord tissues after spinal cord injury and can promote transcription and expression of inflammatory factors in CNS, the expression level of neuroinflammatory factors TNF-alpha, IL-1beta, IL-6, COX-2 and iNOS can be reduced by knocking down ECSCR through siRNA, neuroinflammation is relieved, a new target spot is provided for treating neuroinflammation, and the application value is important.

The application discloses a brain hemorrhage prognosis improvement method based on intestinal flora regulation and relates to the technical field of intestinal microecology.The application comprises the following steps: detecting feces, starting intervention if the enterococcus abundance and neuroinflammatory metabolic markers exceed the standard, stopping the use of conventional nutrient solution, perfusing a special component containing sugar analogs, blocking the energy uptake of enterococcus, simultaneously providing a carbon source for beneficial bacteria, synchronously perfusing a microsphere suspension containing a molecular capture function, adsorbing and fixing proinflammatory metabolic waste in the intestinal tract, blocking the blood entry of the proinflammatory metabolic waste, perfusing live bacteria with different functions three times in time sequence, sequentially completing the acidification of the environment, constructing a bacterial membrane barrier and repairing the intestinal epithelium, and re-detecting after each round of intervention, selecting the maintenance period or adjusting the intensity and then recycling according to the decrease of enterococcus and markers.The application can limit the competitive advantage of enterococcus in the utilization of carbon sources after brain hemorrhage by sequentially implementing competitive inhibition of the phosphotransferase system and multi-species ecological niche occupation.

The invention provides a cassane diterpenoid compound and an application of the cassane diterpenoid compound in preparation of an anti-neuroinflammation medicine. Six novel cassane diterpenoid compounds are separated from mysorethorn, and a preparation method of the six compounds is provided. According to the present invention, the inhibition effect of lipopolysaccharide (LPS)-induced BV-2 microglial cells on NO production is determined, and the six compounds have anti-neuroinflammatory activity, and particularly, the compounds 4 and 5 have good anti-inflammatory effect compared with other compounds, and have the potential of anti-neuroinflammatory drug preparation.

The invention relates to the technical field of biomedical engineering, and discloses a function-integrated drug-loading end component for an invasive neural electrode, a preparation method and the invasive neural electrode. The end component is integrally formed by a medicine-carrying degradable material through a mold and is configured to bear a puncture structure and a long-term medicine slow-release carrier at the same time. The drug-loaded degradable material comprises a compound system of drug-loaded PLGA nanoparticles and polylactic acid, the polylactic acid serves as a continuous phase to provide mechanical support, and the drug-loaded PLGA nanoparticles serve as a filling phase to provide a slow release function; a gradient pore structure formed by gradient volatilization of a double-solvent system is arranged in the end component; and the end component is induced by an interface solvent to form molecular-level fusion connection with the electrode substrate. The risk that a coating falls off due to interface failure in a traditional separation type design is fundamentally eliminated, collaborative optimization of the puncture performance and the slow release performance is achieved, and the end component is endowed with the multi-stage drug release characteristic matched with the neuroinflammatory reaction stage.

The present invention relates to a composition for treating or preventing neurodevelopmental disorders, particularly autism spectrum disorder, by selectively activating brain-resident regulatory T cells (Tregs). The present composition comprises IL-2 or an IL-2 gene (AAV-GFAP-IL-2) as an active ingredient, and induces Treg proliferation in the brain to alleviate neuroinflammation and improve behavioral defects.

The invention discloses application of a Kunlun chrysanthemum aqueous extract in preparation of drugs for improving autism core symptoms, and belongs to the technical field of biological medicines. In order to solve the problem that the prior art lacks a medicine which is small in side effect, natural in source and capable of improving the autism core symptom, the invention provides application of a coreopsis tinctoria aqueous extract in preparation of the medicine for improving the autism core symptom, and the coreopsis tinctoria aqueous extract has a multi-dimensional synergistic effect of adjusting synaptic plasticity, inhibiting neuroinflammation, improving behavioral phenotype and the like. The concept of treating complex nervous system diseases by traditional Chinese medicine is met, and the autism core symptom is fundamentally improved; the medicine containing the coreopsis tinctoria aqueous extract provided by the invention has the advantages of high safety and small side effect.

The present invention provides use of lifitegrast in the preparation of a drug for treating retinal artery occlusion injury. Lifitegrast can effectively reduce retinal artery occlusion injury and apoptosis of retinal ganglion cells and has the effect of inhibiting inflammatory infiltration in the retina and activation of microglia. Moreover, lifitegrast has the effect of reducing retinal ganglion cell injury. Lifitegrast can be used for related diseases such as neuroinflammatory injury caused by retinal artery occlusion.

This invention discloses a micropeptide, its encoding nucleic acid, and its application in regulating inflammatory activation of microglia. The amino acid sequence of the micropeptide is shown in SEQ ID NO:3. Simultaneously, this invention discloses the nucleic acid encoding the micropeptide, which contains either the nucleotide sequence shown in SEQ ID NO:1 or the nucleotide sequence shown in SEQ ID NO:2, wherein SEQ ID NO:2 is a small open reading frame located within the sequence of SEQ ID NO:1. This invention validated the translational expression of the micropeptide in microglia by constructing an EGFP reporter gene fusion vector and a SUMO tag fusion expression vector. Functional experiments showed that under oxygen-glucose deprivation / reperfusion injury conditions, the micropeptide significantly inhibited inflammatory activation of microglia. This invention provides a new potential target and candidate drug for the treatment of neuroinflammatory diseases such as stroke.

The application provides application of a GPR65 agonist in preparation of a medicine for preventing and / or treating Alzheimer's disease, and belongs to the technical field of biological medicine.The application researches and finds that the GPR65 agonist improves the cognitive function of an AD mouse model, reduces neural inflammation and pathological characteristics, and enhances synaptic plasticity.The application provides a molecular target and an intervention window for a treatment strategy in AD research, and provides important theoretical basis and experimental support for subsequent drug development and translational medicine research.

The invention discloses a chitosan modified turmeric-broccoli exosome hybrid nasal spray and application thereof, and belongs to the technical field of biological medicine and drug delivery. The nasal spray is formed by dispersing double plant exosome-lipidosome hybrids in a carrier for nasal cavities. The preparation method comprises the following steps: fusing curcumin carried by a turmeric exosome and sulforaphane carried by a broccoli bud exosome with a pH response liposome membrane containing 1, 2-dioleoyl-sn-glycerol-3-phosphoethanolamine, and modifying by chitosan to form a three-layer structure; the preparation method comprises the steps of exosome extraction, ultrasonic drug loading, liposome hybridization, chitosan coating and preparation blending. The nasal spray is high in entrapment efficiency and uniform in particle size, the chitosan enhances nasal adhesion, inflammation targeted drug release is achieved through pH response, the brain targeting efficiency and stability are excellent, and the adaptability to children is good. The curcumin and sulforaphane are used for targeted therapy of children autism spectrum disorder neuroinflammation, anti-inflammation and anti-oxidation are achieved through synergism of curcumin and sulforaphane, the curative effect is remarkable, and a new scheme is provided for treatment of related diseases.

Tetracycline derivatives and their use as a medicament. In particular, the tetracycline derivatives may be used in the treatment or the prevention of a disease, such as amyloidosis, pain, neurodegenerative diseases and neuroinflammatory diseases, in which the tetracycline derivatives or pharmaceutical compositions including these compounds are administered to a subject in need thereof.

This invention discloses a method for preparing NK cells, the NK cells obtained thereby, and their applications. The method includes: sorting NK cells from peripheral blood of an allogeneic donor; culturing them in a serum-free medium containing CD3 monoclonal antibody, CD16 antibody, and IL-2, without the need for a feeder layer; preferably, IL-21 is added for amplification on days 3-5 of culture, and the cells are cultured for 20-40 days. This method yields non-genetically modified NK cells, among which CD56... bright The NK cells comprise >90% of the cell line and highly express a variety of activating and functional molecules. These NK cells effectively clear Aβ oligomers and senescent cells, and alleviate neuroinflammation. In treatment, intracranial injection achieves equivalent or better efficacy with only about 1 / 10th the dose administered intravenously, significantly clearing Aβ deposits in the brains of AD model mice and improving pathology.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.